HomeCompareHLUBF vs EQR

HLUBF vs EQR: Dividend Comparison 2026

HLUBF yields 3.77% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $27.5K in total portfolio value
10 years
HLUBF
HLUBF
● Live price
3.77%
Share price
$4.82
Annual div
$0.18
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$0.38
Full HLUBF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — HLUBF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLUBFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLUBF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLUBF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLUBF
Annual income on $10K today (after 15% tax)
$320.43/yr
After 10yr DRIP, annual income (after tax)
$0.32/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $4,653.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLUBF + EQR for your $10,000?

HLUBF: 50%EQR: 50%
100% EQR50/50100% HLUBF
Portfolio after 10yr
$34.1K
Annual income
$2,737.99/yr
Blended yield
8.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

HLUBF
No analyst data
Altman Z
2.1
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLUBF buys
0
EQR buys
0
No recent congressional trades found for HLUBF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLUBFEQR
Forward yield3.77%5.87%
Annual dividend / share$0.18$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.8%
Portfolio after 10y$20.3K$47.8K
Annual income after 10y$0.38$5,475.61
Total dividends collected$381.00$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HLUBF vs EQR ($10,000, DRIP)

YearHLUBF PortfolioHLUBF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,888$188.49$11,380$679.82$492.00EQR
2$11,747$95.90$13,014$837.25$1.3KEQR
3$12,617$48.35$14,961$1,036.20$2.3KEQR
4$13,525$24.27$17,297$1,289.22$3.8KEQR
5$14,484$12.15$20,121$1,613.15$5.6KEQR
6$15,503$6.08$23,561$2,030.84$8.1KEQR
7$16,592$3.04$27,783$2,573.54$11.2KEQR
8$17,755$1.52$33,013$3,284.39$15.3KEQR
9$18,998$0.76$39,547$4,223.51$20.5KEQR
10$20,329$0.38$47,791$5,475.61$27.5KEQR

HLUBF vs EQR: Complete Analysis 2026

HLUBFStock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Full HLUBF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this HLUBF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLUBF vs SCHDHLUBF vs JEPIHLUBF vs OHLUBF vs KOHLUBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.